Clinical Trial Update: A Study of the Use of Text Message Reminders to Take Palbociclib [NA]

View source ↗

Summary

This clinical trial update describes a study evaluating whether text message reminders improve adherence to Palbociclib in patients with breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IBRANCE (PALBOCICLIB)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Breast Cancer | NA | Status: ACTIVE_NOT_RECRUITING